Extended Data Fig. 10: Validation of computational deconvolution analysis for activated fibroblasts.
From: Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy
a, in situ hybridization with RNAscope showing localization of canonical fibroblast marker DCN (green/blue), and activated fibroblast marker COL22A1 (red), across single sections derived from 6 patients. Nuclear localization is shown with hematoxylin (blue). The computationally predicted percent of activated fibroblasts from CIBERSORTx (% Act. FB) for each patient is shown above their respective image. b, c, Uniform manifold and projection representation of all nuclei from both the primary analysis (npatient = 42) and validation single-nuclei RNA-sequencing (npatient = 3) (b), and separately for validation samples alone (c). The total number of patients (n_patients) and total nuclei (n_nuclei) are shown above each respective figure. d, Relative contribution of fibroblasts and activated fibroblasts to each primary analysis patient (left) and validation patients only (right). DCM, Dilated cardiomyopathy; HCM, Hypertrophic cardiomyopathy; NF, Non-failing; VSMC, Vascular smooth muscle cell.
